ライフサイエンスコーパス: was significantly lower

1 he control group, and the probability of asthma development was significantly lower.

2 CCT was significantly lower after DMEK-only than after triple-DME

3 The amplitude of activation was significantly lower after infarct and demonstrated a patt

4 The rate of bacteremia was significantly lower among COVID-19 patients (3.8%) than a

5 Antibiotic prescribing was significantly lower among patients who received an initia

6 The reoperation rate was significantly lower among patients who received PPV with

7 is trial involving high-risk persons, lung-cancer mortality was significantly lower among those who underwent volume CT s

8 The rate of HFH was significantly lower at 1 year compared with the year befo

9 Mean pVL at baseline was significantly lower by 1 log for HIV-1/O+ vs HIV-1/M+ pat

10 The participation rate in the control group (17.5%) was significantly lower compared with the sequential (25.8%)

11 However, it was significantly lower for 2 (16.4 vs 29.4), or 3 injections

12 Spending on index surgery was significantly lower for EVR (median [interquartile range]

13 RB1, and -DQB1 haplotypes had no mistakes, and the accuracy was significantly lower for non-Caucasians (29.1%) compared t

14 Within-treatment dispersion was significantly lower for salt and nutrient addition microc

15 nce, the positive-predictive value toward ICM configuration was significantly lower for segmental as compared to whole-ch

16 IPD incidence in children <5 years was significantly lower for serotypes 1 (incidence rate ratio

17 Unadjusted and adjusted risk of death was significantly lower for treated patients compared with co

18 The volume of the surgical specimens was significantly lower in Group B than in Group A (128.68cm3

19 Diagnostic VL was significantly lower in hospitalized patients than in pati

20 Median length of stay was significantly lower in LB group (2.0 versus 3.0; adjusted

21 The median washout coefficient (K (2)) was significantly lower in malignant lesions than in benign l

22 Serious morbidity composite was significantly lower in patients who were discharged early

23 The number of cases of IASCC was significantly lower in persons with HIV engaged in an ana

24 n the 20-mg, 10-mg, and 5-mg groups, respectively; the risk was significantly lower in the 10-mg group than in the 20-mg

25 In comparison, the recovery was significantly lower in the bread sample.

26 years of follow-up (n = 1,775, 9 RCTs), all-cause mortality was significantly lower in the DCB group when compared with c

27 Mean time to first feed was significantly lower in the early feeding group, but not s

28 [(11)C]UCB-J V(T) was significantly lower in the frontal and anterior cingulate

29 Necrotic bone exposure was significantly lower in the FS-M (p = 0.028) and FS-H (p =

30 Colon expression of alpha-SMA was significantly lower in the MODULEN group versus controls

31 In the combined, matched analysis mortality was significantly lower in the paclitaxel device group (8.5%)

32 Serum miR-375 was significantly lower in the peritoneal pouch group than in

33 The brushing duration was significantly lower in the PG group compared to the H gro

34 riencing out-of-hospital cardiac arrest, discharge survival was significantly lower in women than in men, especially amon

35 expression levels of Lrp5, CSF1, and CD105 in tumor tissues was significantly lowered in the Cancer Genome Atlas database

36 came dorsiflexed, but the change in the fascicle gear ratio was significantly lower on the paretic side.

37 the slope of the fascicle gear ratio over ankle joint angle was significantly lower on the paretic side.

38 was significantly higher (P = 0.008), whereas radiodensity was significantly lower (P = 0.006).

39 g the second therapy cycle, tumor uptake of (177)Lu-DOTATOC was significantly lower (P = 0.01) whereas (177)Lu-DOTA-JR11

40 ies was 4.7% (95% confidence interval [CI], 3.6-6.1), which was significantly lower than at baseline (18.7%; relative red

41 98% of patients retained residual BM diffuse uptake, which was significantly lower than at baseline (mainly between BMS

42 SBMI of carriers of normal weight (PRSBMI = -0.64 +/- 0.18) was significantly lower than of carriers with obesity (0.40 +

43 DR of PERFORMS outliers was 7.2 per 1000 women screened and was significantly lower than other readers (nonoutliers) wher

44 The yield of routine protocol EMBs was significantly lower than symptom-triggered EMBs, not only

45 assessment of group 1 was 0.78 (95% CI: 0.70, 0.86), which was significantly lower than that of group 2, 0.92 (95% CI: 0

46 kely pathogenic variants in ATP13A2, PLA2G6, PRKN, or PINK1 was significantly lower than that of non-carriers, while the

47 >=1.00 IU/mL QFT, >=8 spots TSPOT), TST and QFT specificity was significantly lower than TSPOT.

48 ly, the proportion of flies dying after M. luteus infection was significantly lower when flies were fed a low-P high-C di

49 During days 0-69, mean monthly attack rate was significantly lower with lanadelumab (0.41-0.76) vs place

50 The incidence of CMV disease was significantly lower with preemptive therapy than antivira